Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: eric ross who wrote (606)	12/3/2001 4:45:34 PM
From: LemurHouse	Read Replies (1) \| Respond to of 656

Plain ignorance, or the inability to look farther than the current quarter are other explanations. There was an analyst or some such on CNBC this morning saying that Immunex has not solved its supply problems, the plant might not get approved, etc. Telling last spring/summer's story without reference to what the company is doing. He ignored the growing evidence that there will be even greater supply improvements than current projections. They secured additional capacity in Germany, and are reportedly stockpiling inventory that is currently being produced at Rhode Island and which can be put on the market as soon as the plant & processs has been certified. While nothing is guaranteed, it would be very surprising indeed if plant certification doesn't happen considerably in advance of the previously announced schedule, that schedule being necessarily conservative. I believe '02 Enbrel sales will be significantly above current estimates. When that becomes clear the market will pile-on and that's when I'll look to sell. My guess is 2Q next year. FWIW.